Skip to content

Medtech Startup MyoPharm Develops Revolutionary and Reasonably priced Chip expertise to Eradicate Animal testing and Expedite Scientific Trials of Key Medicine in Medical Analysis

ONTARIO, CANADA / ACCESSWIRE / January 16, 2023 / The analysis and improvement of a brand new drug within the pharmaceutical trade is a course of that may take a really very long time as it’s extremely regulated and contains in depth medical trials, first in a laboratory setting, then in animals and eventually in sufferers who’ve signed on willingly as a final choice to be able to check drug security and efficacy. The medical testing of pharmaceutical medication on animals has lengthy been a really controversial matter because of the dangerous affect it will probably have on them. There may be additionally a scarcity of proof that the results of the medication on animals could be much like that on people. A brand new medtech startup referred to as MyoPharm is looking for to scale back the time and expense associated to the drug testing and analysis course of by way of the event of an progressive chip expertise that may mimic the response of human organs to completely different medication.

Commenting on the startup’s bold plans, Mehdi Bagheri, the CEO of MyoPharm stated, “As a pediatric heart specialist with over 20 years of expertise, it was heartbreaking to see many lives being misplaced because of the very long time it took for promising medication to get approval after finishing the medical trials stage.Our new expertise was developed in opposition to a backdrop of heavy odds because of the sanctions in opposition to our native nation, Iran, which meant that we lacked entry to many sources that have been wanted.However, it’s extremely promising as it will probably remove the necessity for in depth testing on animals and human beings.We’ve got developed three varieties of chips that may mimic the actions of key organs just like the lung, coronary heart, liver and gut which can be utilized singly or together.With the registration of our firm in Canada and the transfer right here we hope to additional develop and refine our expertise in order that it will probably have a major affect on medical analysis specifically and on society in common.”

MyoPharm, Monday, January 16, 2023, Press launch image

Credit score: MYO PHARM

Dr. Mehdi, and his group of extremely skilled co-founders, Seyed Bardia Hosseini, Allahyar Montasseri and Leila Fardifallah developed this distinctive expertise in 2019. In the course of the pandemic, additionally they developed a pump by way of which media might be injected into the chips in order that it replicates the functioning of the person organs. The character of cells in every organ is extremely differentiated and sophisticated, therefore, every kind of chip was developed as an final result of many months of analysis. MyoPharm has already acquired a patent for its distinctive pump expertise that makes it potential for the chips to perform.

Stated Dr. Mehdi Bagheri, “I’ve printed over 25 scientific articles about cardiac issues and intervention in cardiac illness in reputed scientific journals. Our path breaking expertise is predicated on stable analysis and can be extremely helpful to firms within the CRAMS (Contract Analysis and “Manufacturing) house for creating medication with out the necessity for testing on animals or in depth medical trials. That is expertise that may change the course of hundreds of lives throughout the globe.”

In the long term, MyoPharm plans to associate with different firms and develop its vary of chips to cowl testing for ailments linked to extra organs within the physique. For many individuals affected by ailments like Congestive Coronary heart Failure (CHF) and Coronary Artery Illness (CAD), the price of medicines and issues about animal testing are very actual. Corporations like MyoPharm could make a major affect on the fee and effectiveness of medicine and expedite the drug improvement cycle.

About MyoPharm: MyoPharm is a medtech firm that focuses on progressive and inexpensive chip expertise for expediting analysis and improvement of pathbreaking pharmaceutical medication.

Media Contact:

Identify: Allahyar Montasseri (Media and funding relations)
E-mail: information@myopharm.ca

SOURCE: MyoPharm

View supply model on accesswire.com:
https://www.accesswire.com/735384/Medtech-Startup-MyoPharm-Develops-Revolutionary-and-Reasonably priced-Chip-technology-to-Eradicate-Animal-testing-and-Expedite-Scientific-Trials-of-Key- Medicine-in-Medical-Analysis

Leave a Reply

Your email address will not be published. Required fields are marked *